Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis

Urology

Volumn 75, Issue 6, 2010, Pages 1446-1451

  Kamiya, Naoto ^a   Suzuki, Hiroyoshi ^a   Yano, Masashi ^a   Endo, Takumi ^a   Takano, Makoto ^a   Komaru, Atsuhi ^a   Kawamura, Koji ^a   Sekita, Nobuyuki ^a   Imamoto, Takashi ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL PYRIDINOLINE CROSS LINKED TELOPEPTIDE PART OF TYPE 1 COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ACID PHOSPHATASE; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BONE NEOPLASMS; COHORT STUDIES; COLLAGEN TYPE I; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952744275     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.11.049     Document Type: Article

References (30)

1. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
2. Oefelein M.G., Ricchiuti V., Conrad W., et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005-1007
3. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 (2001) 165-176
4. Rosenthal D.I. Radiologic diagnosis of bone metastases. Cancer 80 (1997) 1595-1607
5. Citrin D.L., Bessent R.G., and Greig W.R. A comparison of the sensitivity and accuracy of the 99TCm-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases. Clin Radiol 28 (1997) 107-117
6. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17 (1999) 948-957
7. Corrie D., Timmons J.H., Bauman J.M., et al. Efficacy of follow-up bone scans in carcinoma of the prostate. Cancer 61 (1988) 2453-2454
8. Oesterling J.E., Martin S.K., Bergstralh E.J., et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 (1993) 57-60
9. Akimoto S., Furuya Y., Akakura K., et al. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade. Prostate 38 (1999) 28-34
10. Nakashima J., Sumitomo M., Miyajima A., et al. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol 157 (1997) 1736-1739
11. Ozu C., Nakashima J., Horiguchi Y., et al. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 15 (2008) 419-422
12. Noguchi M., and Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166 (2001) 1106-1110
13. Hegele A., Wahl H.G., Varga Z., et al. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 99 (2007) 330-334
14. Miyaji Y., Saika T., Yamamoto Y., et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64 (2004) 128-131
15. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
16. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988) 195-202
17. Saad F., Gleason D.M., Murray R., et al., Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
18. Smith Jr. J.A., Lange P.H., Janknegt R.A., et al. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 157 (1997) 1329-1334
19. Mose S., Menzel C., Kurth A.A., et al. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients. Anticancer Res 23 (2003) 2783-2788
20. Koopmans N., de Jong I.J., Breeuwsma A.J., et al. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178 (2007) 849-853
21. Koga H., Naito S., Koto S., et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39 (1999) 1-7
22. Gutman E.B., Sproul E.E., and Gutman A.B. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28 (1936) 485-495
23. Bishop M.C., Hardy J.G., Taylor M.C., et al. Bone imaging and serum phosphatases in prostatic carcinoma. Br J Urol 57 (1985) 317-324
24. Chybowski F.M., Larson Keller J.J., Bergstralh E.J., et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145 (1991) 313-318
25. Wymenga L.F., Boomsma J.H., Groenier K., et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 88 (2001) 226-230
26. Hill C.S., and Wolfert R.L. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 186 (1989) 315-320
27. Lorente J.A., Valenzuela H., Morote J., et al. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26 (1999) 625-632
28. Halleen J.M. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23 (2003) 1027-1029
29. Halleen J.M., Alatalo S.L., Janckila A.J., et al. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47 (2001) 597-600
30. Woitge H.W., Pecherstorfer M., Li Y., et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14 (1999) 792-801